Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Danielle A Griffin

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Scientific Reports|January 3, 2025
Immunologic investigations into transgene directed immune-mediated myositis following delandistrogene moxeparvovec gene therapyRachael A Potter, Ida H Moeller, Sohrab Khan, et al.
Human Gene Therapy|July 15, 2017
Systemic Delivery of Dysferlin Overlap Vectors Provides Long-Term Gene Expression and Functional Improvement for DysferlinopathyRachael A Potter, Danielle A Griffin, Patricia C Sondergaard, et al.
Nature Medicine|January 4, 2024
Gene therapy with bidridistrogene xeboparvovec for limb-girdle muscular dystrophy type 2E/R4: phase 1/2 trial resultsJerry R Mendell, Eric R Pozsgai, Sarah Lewis, et al.
Muscle & Nerve|August 14, 2023
Long-term safety and functional outcomes of delandistrogene moxeparvovec gene therapy in patients with Duchenne muscular dystrophy: A phase 1/2a nonrandomized trialJerry R Mendell, Zarife Sahenk, Kelly J Lehman, et al.
Human Gene Therapy|March 7, 2019
Gene Delivery for Limb-Girdle Muscular Dystrophy Type 2D by Isolated Limb InfusionJerry R Mendell, Louis G Chicoine, Samiah A Al-Zaidy, et al.
Annals of Neurology|August 4, 2023
Delandistrogene Moxeparvovec Gene Therapy in Ambulatory Patients (Aged ≥4 to <8 Years) with Duchenne Muscular Dystrophy: 1-Year Interim Results from Study SRP-9001-103 (ENDEAVOR)Craig M Zaidman, Crystal M Proud, Craig M McDonald, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|October 23, 2013
Vascular delivery of rAAVrh74.MCK.GALGT2 to the gastrocnemius muscle of the rhesus macaque stimulates the expression of dystrophin and laminin α2 surrogatesLouis G Chicoine, Louise R Rodino-Klapac, Guohong Shao, et al.
JAMA Neurology|June 16, 2020
Assessment of Systemic Delivery of rAAVrh74.MHCK7.micro-dystrophin in Children With Duchenne Muscular Dystrophy: A Nonrandomized Controlled TrialJerry R Mendell, Zarife Sahenk, Kelly Lehman, et al.
Molecular Therapy. Methods & Clinical Development|August 4, 2018
An Isolated Limb Infusion Method Allows for Broad Distribution of rAAVrh74.MCK.<i>GALGT2</i> to Leg Skeletal Muscles in the Rhesus MacaqueRui Xu, Ying Jia, Deborah A Zygmunt, et al.
Frontiers in Cell and Developmental Biology|July 27, 2023
Expression of SRP-9001 dystrophin and stabilization of motor function up to 2 years post-treatment with delandistrogene moxeparvovec gene therapy in individuals with Duchenne muscular dystrophyJerry R Mendell, Perry B Shieh, Craig M McDonald, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Scientific Reports|January 3, 2025
Immunologic investigations into transgene directed immune-mediated myositis following delandistrogene moxeparvovec gene therapyRachael A Potter, Ida H Moeller, Sohrab Khan, et al.
Human Gene Therapy|July 15, 2017
Systemic Delivery of Dysferlin Overlap Vectors Provides Long-Term Gene Expression and Functional Improvement for DysferlinopathyRachael A Potter, Danielle A Griffin, Patricia C Sondergaard, et al.
Nature Medicine|January 4, 2024
Gene therapy with bidridistrogene xeboparvovec for limb-girdle muscular dystrophy type 2E/R4: phase 1/2 trial resultsJerry R Mendell, Eric R Pozsgai, Sarah Lewis, et al.
Muscle & Nerve|August 14, 2023
Long-term safety and functional outcomes of delandistrogene moxeparvovec gene therapy in patients with Duchenne muscular dystrophy: A phase 1/2a nonrandomized trialJerry R Mendell, Zarife Sahenk, Kelly J Lehman, et al.
Human Gene Therapy|March 7, 2019
Gene Delivery for Limb-Girdle Muscular Dystrophy Type 2D by Isolated Limb InfusionJerry R Mendell, Louis G Chicoine, Samiah A Al-Zaidy, et al.
Annals of Neurology|August 4, 2023
Delandistrogene Moxeparvovec Gene Therapy in Ambulatory Patients (Aged ≥4 to <8 Years) with Duchenne Muscular Dystrophy: 1-Year Interim Results from Study SRP-9001-103 (ENDEAVOR)Craig M Zaidman, Crystal M Proud, Craig M McDonald, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|October 23, 2013
Vascular delivery of rAAVrh74.MCK.GALGT2 to the gastrocnemius muscle of the rhesus macaque stimulates the expression of dystrophin and laminin α2 surrogatesLouis G Chicoine, Louise R Rodino-Klapac, Guohong Shao, et al.
JAMA Neurology|June 16, 2020
Assessment of Systemic Delivery of rAAVrh74.MHCK7.micro-dystrophin in Children With Duchenne Muscular Dystrophy: A Nonrandomized Controlled TrialJerry R Mendell, Zarife Sahenk, Kelly Lehman, et al.
Molecular Therapy. Methods & Clinical Development|August 4, 2018
An Isolated Limb Infusion Method Allows for Broad Distribution of rAAVrh74.MCK.<i>GALGT2</i> to Leg Skeletal Muscles in the Rhesus MacaqueRui Xu, Ying Jia, Deborah A Zygmunt, et al.
Frontiers in Cell and Developmental Biology|July 27, 2023
Expression of SRP-9001 dystrophin and stabilization of motor function up to 2 years post-treatment with delandistrogene moxeparvovec gene therapy in individuals with Duchenne muscular dystrophyJerry R Mendell, Perry B Shieh, Craig M McDonald, et al.
Pageof 2